Antibodies targeting interleukin 6 (IL-6) are currently being evaluated in clinical trials for the treatment of uveitic macular edema and are discussed for their therapeutic potential in macular edema due to retinal neovascular disease.11 This evidence concerns the gene IL6 and macular retinal edema.